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Abstract This study aimed to systematically review the prog-
nostic value of interim and end-of-treatment 18F-fluoro-2-de-
oxy-D-glucose positron emission tomography (FDG-PET) in
follicular lymphoma during and after first-line therapy. The
PubMed/MEDLINE database was searched for relevant orig-
inal studies. Included studies were methodologically assessed,
and their results were extracted and descriptively analyzed.
Three studies on the prognostic value of interim FDG-PET
and eight studies on the prognostic value of end-of-treatment
FDG-PETwere included. Overall, studies were of poor meth-
odological quality. In addition, there was incomplete reporting
of progression-free survival (PFS) and overall survival (OS)
data by several studies, and none of the studies incorporated
the Follicular Lymphoma International Prognostic Index
(FLIPI) in the OS analyses. Two studies reported no signifi-
cant difference in PFS between interim FDG-PET positive
and negative patients, whereas one study reported a significant
difference in PFS between the two groups. Two studies report-
ed no significant difference in OS between interim FDG-PET
positive and negative patients. Five studies reported end-of-
treatment FDG-PET positive patients to have a significantly
worse PFS than end-of-treatment FDG-PET negative patients,
and one study reported a non-significant trend towards a
worse PFS for end-of-treatment FDG-PET positive patients.
Three studies reported end-of-treatment FDG-PET positive
patients to have a significantly worse OS than end-of-
treatment FDG-PET negative patients. In conclusion, the
available evidence does not support the use of interim FDG-
PET in follicular lymphoma. Although published studies sug-
gest end-of-treatment FDG-PET to be predictive of PFS and
OS, they suffer from numerous biases and failure to correct
OS prediction for the FLIPI.
Keywords End-of-treatment . FDG-PET . Follicular
lymphoma . Interim . Systematic review
Introduction
Follicular lymphoma is the second most frequently occurring
non-Hodgkin lymphoma subtype [1]. In contrast to the 2007
Revised Response Criteria for Malignant Lymphoma [2] that
considered computed tomography (CT) as the standard meth-
od for therapy response assessment in follicular lymphoma,
the recently published Lugano Classification recommends
using 18F-fluoro-2-deoxy-D-glucose positron emission tomog-
raphy (FDG-PET) in follicular lymphoma [3, 4]. Moreover,
the current guidelines also advocate the use of interim FDG-
PET during treatment, although they do no support changing
therapeutic strategy on the basis of interim FDG-PET findings
outside clinical trials [3, 4]. Despite the recommendations in
the new guidelines, there is still considerable debate on the
utility of FDG-PET for therapy response assessment in follic-
ular lymphoma and, not surprisingly, wide variability in the
use of FDG-PET in these settings among different institutions.
This debate on and the variability in the application of FDG-
PET in follicular lymphoma reflect the need for evidence-
based data. Although individual studies can provide more in-
sight, there may be variability among individual studies with
regard to internal validity (i.e., risk of bias) and external va-
lidity (i.e., generalizability of the study results). To overcome
the limitations of individual studies, a systematic review is
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required. The purpose of this study was therefore to system-
atically review published data on the prognostic value of in-
terim and end-of-treatment FDG-PET in follicular lymphoma.
Materials and methods
Search strategy
A systematic literature search was performed in the PubMed/
MEDLINE database using the search terms that are displayed
in Table 1. The search covered the period from start date to
March 20, 2015. The reference lists of all studies that were
finally included were screened for potentially suitable articles
that were not detected by the initial search.
Study selection
Original studies that reported on the prognostic value of inter-
im or end-of-treatment FDG-PET in indolent (grade 1-3A)
follicular lymphoma during or after first-line therapy were
included. Only studies written in English, German, Italian,
French, Spanish, or Dutch were included. Studies without
patient data (guidelines, reviews, meta-analyses, editorials,
and letters), studies including less than ten patients with fol-
licular lymphoma, duplicate studies, conference abstracts,
studies that did not allow data extraction of patients with fol-
licular lymphoma patients from patients with other lymphoma
subtypes, studies that included patients with refractory dis-
ease, studies in which patients received second-line therapy,
and studies that tailored the therapy on the basis of the interim
or end-of-treatment FDG-PET result were excluded. Titles
and abstracts of all studies that were obtained by the
PubMed/MEDLINE search were scrutinized, and clearly in-
eligible studies were excluded at this stage. The full-text ver-
sions of the remaining articles were then evaluated, and a final
decision was made as to whether or not a study met the criteria
to be included in the systematic review.
Study quality
The Quality In Prognosis Studies (QUIPS) tool [5], which was
developed to assess the risk of bias in prognostic studies, was
used for the methodological quality assessment. The QUIPS
tool assesses the risk of bias in six different domains: study
participation (Bdoes the study population adequately represent
the population of interest?^), study attrition (Bdo the study
data available [i.e., patients not lost to follow-up] adequately
represent the study sample?^), prognostic factor measurement
(Bis the prognostic factor measured in a similar way for all
participants?^), outcome measurement (Bis the outcome of
interest measured in a similar way for all participants?^), study
confounding (Bhave important potential confounding factors
appropriately been accounted for?^), and statistical analysis
and reporting (Bis the statistical analysis appropriate, and are
all primary outcomes reported^) [5]. Risk of bias was scored
Blow,^ Bmoderate,^ or Bhigh for these six domains.
Data analysis




The literature search revealed a total of 651 articles (Table 1).
After screening titles and abstracts, 41 potentially relevant
articles remained and were retrieved and read in full-text for-
mat. Of these 41 articles, 16 were excluded because the prog-
nostic value of interim or end-of-treatment FDG-PET status
was not reported, 6 were excluded because of inclusion of less
than 10 patients with follicular lymphoma, 4 were excluded
because data of patients with follicular lymphoma could not
be separated from patients with other lymphoma subtypes, 4
were excluded because of (partial) inclusion of patients with
refractory disease, 1 was excluded because it only included
patients with transformed lymphomas, 1 was excluded be-
cause it reported data that were also used in another (larger)
study, and 1 was excluded because it was written in Japanese.
Thus, eight studies remained. Of these eight studies, three
reported data on the prognostic value of interim FDG-PET
and eight studies reported data on the prognostic value of
end-of-treatment FDG-PET. Characteristics and applied meth-
odology of the eight included studies are displayed in Tables 2
and 3.
Table 1 Search strategy and results as on March 20, 2015
No. Search string PubMed/Medline
1. Fluorodeoxyglucose OR 2-fluoro-2-deoxy-D-glucose OR FDG OR 18F-FDG OR positron emission tomography OR PET 86,557
2. Follicular OR indolent 62,338
3. No. 1 AND No. 2 651
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Methodological quality assessment
Results of the methodological quality assessment using the
QUIPS tool are shown in Table 4. There was high risk of bias
in one study for both the domains study participation and
study confounding because this study only included cases that
were clearly positive or negative and excluded cases that were
not unequivocally positive or negative [7]. There was high
risk of bias for the domain prognostic factor measurement in
four studies [7, 8, 10, 13] because these studies did not report
clear criteria for FDG-PET positivity/negativity, and there was
moderate risk of bias for the domain prognostic factor mea-
surement in three other studies because one study [9] did not
report which PETsystem (modern hybrid PET/CTor diagnos-
tically inferior stand-alone PET) was used for FDG imaging
and two studies [6, 12] reported that (some of) the included
patients underwent stand-alone FDG-PET. Finally, there was
high risk of bias for outcome measurement in all eight studies
[6–13], because none of the eight studies reported clear and
reproducible criteria for disease progression/relapse/end of
progression-free survival (PFS), three studies [6, 7, 11] did
not report whether follow-up visits/examinations were stan-
dardized or similar in both the FDG-PET negative and posi-
tive group, and five of eight studies [7, 8, 11–13] failed to
provide data on the overall survival (OS).
Interim FDG-PET
The results of the three studies reporting on the prognostic
value of interim FDG-PET are shown in Table 5. The propor-
tion of interim FDG-PET negative and positive patients ranged
from 64 to 76 % and 24.3 to 36.4 %, respectively. All three
studies investigated the association of the interim FDG-PET
result with PFS, with two studies reporting no significant dif-
ference in PFS between FDG-PET positive and negative pa-
tients [6, 12], whereas one study [9] reported FDG-PET posi-
tive patients to have a significantly worse PFS than FDG-PET
negative patients [9]. Only two of three studies investigated the
association of the interim FDG-PET result with OS, with both
studies reporting no significant difference in OS between FDG-
Table 2 Characteristics of included studies and patients
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Additional maintenance R, 45
Luminari et al. [7]
(2014)




R-CVP, 66 R-CHOP, 62 R-FM, 74
Zinzani et al. [8]
(2013)
Italy Retrospective 142 63a (25–83) 55/87 III, 65
IV, 77
NR R-FM
Dupuis et al. [9]
(2012)






2× additional R, 106
Trotman et al. [10]
(2011)





6× R-CHOP + 2× R, 103
8× R-CVP, 19
Le Dortz et al. [11]
(2010)







Bishu et al. [12]
(2007)
USA Retrospective 16 NR NR II, 3
III, 5
IV, 8
NR CHOP, R-CHOP, CNOP, CVP,
R-monotherapy with/without
additional RT
Zinzani et al. [13]
(2007)
Italy Retrospective 45 55b (31–78) 25/20 III/IV, 40 2, 28 ≥
3, 17
R-FM or R-CHOP
CHOP cyclophosphamide, doxorubicin, vincristine, and prednisone; CNOP cyclophosphamide, mitoxantrone, vincristine, and prednisone; CVP cyclo-
phosphamide, vincristine, and prednisone; FM rituximab, fludarabine, and mitoxantrone; ICE ifosfamide, carboplatin, etoposide; NR not reported; R
rituximab; RT radiation therapy
aNumber of patients who were included in this study of whom baseline characteristics were available
bMedian
cMean
d FLIPI score [14]
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PET positive and negative patients [6, 9]. Of interest, none of
the studies corrected the interim FDG-PET result for the pre-
dictive value of the Follicular Lymphoma International
Prognostic Index (FLIPI) in the OS analyses.
End-of-treatment FDG-PET
The results of the eight studies reporting on the prognostic value
of end-of-treatment FDG-PET are displayed in Table 6. The
proportion of end-of-treatment FDG-PET negative and positive
patients ranged from 71.1 to 87.5 % and 12.5 to 28.9 %, respec-
tively. Of the eight studies, six investigated the association of the
end-of-treatment FDG-PET result with PFS, with five studies
reporting FDG-PET positive patients to have a significantly
worse PFS than FDG-PET negative patients [7–11] and one
study reporting a non-significant trend towards a worse PFS for
FDG-PET positive patients [6]. Yet, another two studies did not
report whether there was any significant difference in PFS be-
tween FDG-PET positive and negative patients [12, 13]. Only
four of eight studies investigated the association of the end-of-
treatment FDG-PET result with OS, with three studies reporting
FDG-PET positive patients to have a significantly worse OS than
FDG-PET negative patients [6, 9, 10], whereas one study did not
report whether there was any significant difference in OS be-
tween FDG-PET positive and negative patients [7]. Of interest,
none of the studies corrected the end-of-treatment FDG-PET
result for the predictive value of the FLIPI in the OS analyses.
Discussion
This systematic review included three studies on the prognos-
tic value of interim-FDG-PET and eight studies on the prog-
nostic value of end-of-treatment FDG-PET in follicular lym-
phoma. The results show that there is a lack of data supporting
the use of interim FDG-PET for the evaluation of first-line
therapy in follicular lymphoma, given the fact that interim
FDG-PET was reported to be not predictive of PFS in two of
three studies and was not found to be predictive of OS in the
two available studies on this topic. On the other hand, end-of-
treatment FDG-PET seems to have some predictive value
based on the available studies, with five studies reporting a
significant and one study reporting a nearly significant asso-
ciation with PFS and three studies reporting a significant re-
lationship between end-of-treatment FDG-PET status and OS.
Importantly, however, these results should be interpreted very
cautiously due to the overall poor methodological quality of
included studies. There was high risk of bias with regard to study
participation and confounding in one study (due to the exclusion
of unequivocal FDG-PET cases), moderate and high risk of bias
with regard to prognostic factor measurement in three and four
studies, respectively (due to the [possible] use of diagnostically
inferior stand-alone PET systems and lack of reporting of FDG-
PET interpretation criteria, respectively), and high risk of bias
with regard to outcome measurement in all eight studies. The
latter is due to several important reasons, the first being the fact
that the reference standard may have been different between
FDG-PET positive and negative patients in three studies. This
is of particular concern in retrospective studies, because it is not
uncommon that patients with residual disease according to FDG-
PETare monitored more closely, with more follow-up visits and
more follow-up imaging and laboratory examinations, which
will result in an earlier detection of (asymptomatic) progressions
in this group compared to the FDG-PET negative group. This
may have seriously biased the reported prognostic values of
FDG-PET. Second, none of the included studies reported clear
and reproducible criteria for disease progression/relapse/end of
PFS. Various definitions are used for end of PFS in follicular
lymphoma: first clinical/radiological evidence of disease after
attaining complete remission (not applicable in end-of-
treatment FDG-PET positive cases), increase in FDG avidity at
follow-up FDG-PET, increase in tumor volume at follow-up CT,
alterations in laboratory assessments, development of symptom-
atic disease, histological evidence of high-grade disease














Lu et al. [6] (2014) Low Low Moderate High Low Low
Luminari et al. [7] (2014) High Low High High High Low
Zinzani et al. [8] (2013) Low Low High High Low Low
Dupuis et al. [9] (2012) Low Low Moderate High Low Low
Trotman et al. [10] (2011) Low Low High High Low Low
Le Dortz et al. [11] (2010) Low Low Low High Low Low
Bishu et al. [12] (2007) Low Low Moderate High Low Low
Zinzani et al. [13] (2007) Low Low High High Low Low
Low low risk of bias, Moderate moderate risk of bias, High high risk of bias
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transformation, and initiation of second-line therapy or death. It
should also be noted that the majority of included studies only
reported the PFS and not the OS or the interval between end-of-
treatment FDG-PETand initiation of the next therapy cycle. End
of PFS, when defined as (asymptomatic) disease progression
detected by radiological studies, is not a sufficient indication
for second-line treatment initiation or changing patient manage-
ment otherwise. None of the studies reported data on the value of
FDG-PET in predicting the interval between end-of-treatment
and (re)development of symptomatic disease or time interval
between the end-of-treatment and the initiation of a subsequent
second-line therapy, which can be regarded as perhaps more
important outcomemeasures. Thus, it should be emphasized that
the definition of PFS that is employed by many studies is not the
most important outcome measure in this disease entity, and that
although the results of this systematic review may suggest that a
positive end-of-treatment FDG-PET may be associated with a
worse PFS, it does not support the use of end-of-treatment
FDG-PET in routine clinical practice. Overall, the subjectivity
of the outcome measure PFS and the fact that the PFS do not
provide very clinically relevant data underline that future studies
should focus in particular on the OS or the time interval to de-
velop subsequent symptomatic disease requiring second-line
therapy. Finally, and surprisingly, none of the included studies
corrected the end-of-treatment FDG-PET result for the predictive
value of the FLIPI [14] in the OS analyses. Until end-of-
treatment FDG-PET is proven to be predictive of OS, indepen-
dently of the (less expensive) FLIPI, it cannot be recommended
yet for routine use in clinical practice.
There are several factors that make the role of FDG-PET in
follicular lymphoma more devious in contrast to that in aggres-
sive non-Hodgkin lymphomas and Hodgkin lymphoma. First,
follicular lymphoma is an incurable disease as a result of which
absence of viable tumor at FDG-PET never signifies absence of
residual tumor cells but rather that the majority of the tumor
bulk has responded and made the lymphoma undetectable by
FDG-PET. Disappearance of lymphoma from the BFDG-PET
radar^, may indicate a long-term (asymptomatic) remission, but
not cure. Second, since viable tumor at FDG-PET in follicular
lymphoma is not a direct indication for treatment initiation [1],
detection of residual disease at end-of-treatment FDG-PET
may be less relevant in follicular lymphoma than in aggressive
non-Hodgkin lymphoma and Hodgkin lymphoma where resid-
ual disease after first-line therapy will often result in rapid ad-
ditional diagnostic work-up with eventual consolidation radia-
tion therapy or initiation of second-line therapies [3, 4, 15].
Third, in follicular lymphoma, bone marrow involvement is
present in approximately 50 % of patients [14]. However,
FDG-PET has proven to be inadequately sensitive for the de-
tection of bone marrow involvement in follicular lymphoma
[11, 16]. This in turn proves that FDG-PET cannot be used
either for the evaluation of response to treatment of follicular
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to the more aggressive histologies, determination of the prog-
nostic value of interim and end-of-treatment FDG-PET for
predicting OS requires very long follow-up times, and results
are not rarely biased by variations in the initiation, nature and
intensity of post-first-line therapy, and other, non-lymphoma-
related causes of death.
The present systematic review had limitations. First, it was
not possible to meta-analyze the results of individual studies,
because there was considerable variation in data reporting, and
hazard ratios for PFS and OS were not reported in the majority
of included studies. Second, only a minority of studies reported
the value of FDG-PET in predicting OS and no study reported
data on the time to subsequent treatment initiation of second-
line therapy or time interval to (re)develop asymptomatic dis-
ease after treatment. Third, applied treatment regimens among
the included studies were heterogeneous, which affects
interstudy comparisons. Fourth, the included studies reported
follow-up times ranging between 6 and 104 months, which is
insufficiently long considering the generally prolonged survival
of patients with follicular lymphoma after first-line treatment.
In conclusion, the available evidence does not support the
use of interim FDG-PET in follicular lymphoma. Although
published studies suggest end-of-treatment FDG-PET to be
predictive of PFS and OS, they suffer from numerous biases
and failure to correct OS prediction for the FLIPI.
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